SCHEMBL778942

SCHEMBL778942

[CH2]/C=[C]/C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2504052 0.67
SCHEMBL2400269 0.59
SCHEMBL6183389 0.59
SCHEMBL15219 0.59
SCHEMBL108872 0.59
SCHEMBL2400267 0.59
SCHEMBL9172347 0.59
SCHEMBL232975 0.59
SCHEMBL15068 0.59
SCHEMBL5735436 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118339156-A 2-Diazo-3-oxo-2, 3-dihydrospiro [ indene-1, 9' -xanthene ] derivatives and similar compounds as photoactive fluorescent compounds for protein labelling 爱康治疗公司 2024-07-12 CN disclosed
US-20240226132-A1 RNA COMPOSITIONS COMPRISING A BUFFER SUBSTANCE AND METHODS FOR PREPARING, STORING AND USING THE SAME BIONTECH DELIVERY TECHNOLOGIES GMBH (DE) 2024-07-11 US disclosed
WO-2024133635-A1 COMPOSITION BIONTECH DELIVERY TECHNOLOGIES GMBH (DE) 2024-06-27 WO disclosed
US-20240180941-A1 ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE FLAGSHIP PIONEERING INNOVATIONS V INC (US) 2024-06-06 US disclosed
EP-4377311-A1 2-DIAZO-3-OXO-2,3-DIHYDROSPIRO[INDENE-1,9'-XANTHENE] DERIVATIVES AND SIMILAR COMPOUNDS AS PHOTOACTIVE FLUORESCENT COMPOUNDS FOR PROTEIN LABELING Eikon Therapeutics Inc. (US) 2024-06-05 EP disclosed
US-11998610-B2 Conjugates and methods of using the same FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2024-06-04 US disclosed
US-11981703-B2 Polynucleotide constructs SIRIUS THERAPEUTICS, INC. (US) 2024-05-14 US disclosed
EP-4351553-A1 NOVEL ANTI-FIBROTIC DRUGS Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH (DE) 2024-04-17 EP disclosed
CN-117642185-A Improved CD30 targeting antibody drug conjugates and uses thereof 路德维希-马克西米利安慕尼黑大学 2024-03-01 CN disclosed
CN-117615752-A RNA compositions comprising buffer substances and methods of making, storing, and using the same 生物技术欧洲股份公司 2024-02-27 CN disclosed
WO-2001019780-A2 NOVEL DERIVATIVES OF DICARBOXYLIC ACID HAVING PHARMACEUTICAL PROPERTIES BAYER AKTIENGESELLSCHAFT (DE) 2001-03-22 WO disclosed
WO-2000064583-A1 METAL CATALYSTS AND METHODS FOR MAKING AND USING SAME THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2000-11-02 WO disclosed
WO-2000035903-A2 THIOCHROMANOYL CYCLOHEXENONE DERIVATIVES BASF AKTIENGESELLSCHAFT (DE) 2000-06-22 WO disclosed
US-5180718-A Antilipemic Agents CIBA-GEIGY CORPORATION (US) 1993-01-19 US disclosed
EP-0475895-A1 Acyl derivatives of rifamycins and their use as medicaments CIBA-GEIGY AG (CH) 1992-03-18 EP disclosed
EP-0475896-A1 Polycyclic compounds CIBA-GEIGY AG (CH) 1992-03-18 EP disclosed
EP-0434621-A2 Rifamycin derivatives and processes for the manufacture thereof CIBA-GEIGY AG (CH) 1991-06-26 EP disclosed
US-5003070-A Antilipemic agents; arteriosclerosis; antibiotics CIBA-GEIGY CORPORATION (US) 1991-03-26 US disclosed
EP-0385405-A2 Acyl derivatives CIBA-GEIGY AG (CH) 1990-09-05 EP disclosed
EP-0350445-A1 Substituted azacyclohexyl derivatives CIBA-GEIGY AG (CH) 1990-01-10 EP disclosed